Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia F Simard

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Rheumatic Diseases Clinics of North America|September 28, 2020
Increasing Ancestral Diversity in Lupus Trials: Ways ForwardTitilola Falasinnu, Yashaar Chaichian, Julia F Simard
Annals of the Rheumatic Diseases|December 15, 2010
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in SwedenMartin Neovius, Julia F Simard, Johan Askling, et al.
Arthritis and Rheumatism|March 20, 2013
Reply: To PMID 22886739Julia F Simard, Martin Neovius, Johan Askling
Clinical Rheumatology|February 20, 2021
Pulse dose steroid experience among hospitalized patients with systemic lupus erythematosus: a single-center feasibility studyYashaar Chaichian, Michael H Weisman, Julia F Simard
ACR Open Rheumatology|November 29, 2019
Unraveling Race, Socioeconomic Factors, and Geographical Context in the Heterogeneity of Lupus Mortality in the United StatesTitilola Falasinnu, Yashaar Chaichian, Latha Palaniappan, et al.
Epidemiology (Cambridge, Mass.)|May 10, 2008
Exposure to cigarette smoke in utero: comparison of reports from mother and daughterJulia F Simard, Bernard A Rosner, Karin B Michels
Public Health Reports (Washington, D.C. : 1974)|June 22, 2018
Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013Titilola Falasinnu, Marios Rossides, Yashaar Chaichian, et al.
Arthritis and Rheumatism|February 10, 2011
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsPauline Raaschou, Julia F Simard, Martin Neovius, et al.
BMJ (Clinical Research Ed.)|April 10, 2013
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from SwedenPauline Raaschou, Julia F Simard, Marie Holmqvist, et al.
BMJ (Clinical Research Ed.)|January 30, 2016
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from SwedenPauline Raaschou, Julia F Simard, Charlotte Asker Hagelberg, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Rheumatic Diseases Clinics of North America|September 28, 2020
Increasing Ancestral Diversity in Lupus Trials: Ways ForwardTitilola Falasinnu, Yashaar Chaichian, Julia F Simard
Annals of the Rheumatic Diseases|December 15, 2010
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in SwedenMartin Neovius, Julia F Simard, Johan Askling, et al.
Arthritis and Rheumatism|March 20, 2013
Reply: To PMID 22886739Julia F Simard, Martin Neovius, Johan Askling
Clinical Rheumatology|February 20, 2021
Pulse dose steroid experience among hospitalized patients with systemic lupus erythematosus: a single-center feasibility studyYashaar Chaichian, Michael H Weisman, Julia F Simard
ACR Open Rheumatology|November 29, 2019
Unraveling Race, Socioeconomic Factors, and Geographical Context in the Heterogeneity of Lupus Mortality in the United StatesTitilola Falasinnu, Yashaar Chaichian, Latha Palaniappan, et al.
Epidemiology (Cambridge, Mass.)|May 10, 2008
Exposure to cigarette smoke in utero: comparison of reports from mother and daughterJulia F Simard, Bernard A Rosner, Karin B Michels
Public Health Reports (Washington, D.C. : 1974)|June 22, 2018
Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013Titilola Falasinnu, Marios Rossides, Yashaar Chaichian, et al.
Arthritis and Rheumatism|February 10, 2011
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsPauline Raaschou, Julia F Simard, Martin Neovius, et al.
BMJ (Clinical Research Ed.)|April 10, 2013
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from SwedenPauline Raaschou, Julia F Simard, Marie Holmqvist, et al.
BMJ (Clinical Research Ed.)|January 30, 2016
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from SwedenPauline Raaschou, Julia F Simard, Charlotte Asker Hagelberg, et al.
Pageof 13